
  
    
      
        Background_NNP
        Resistance_NNP to_TO acyclovir_NN (_( ACV_NNP )_) or_CC penciclovir_NN (_( PCV_NNP )_)
        generally_RB arises_VBZ by_IN a_DT single_JJ base_NN mutation_NN in_IN either_DT the_DT
        HSV_NNP thymidine_NN kinase_NN (_( TK_NNP )_) or_CC DNA_NNP polymerase_NN (_( Pol_NNP )_) gene_NN [_NN for_IN
        a_DT review_NN ,_, see_VB reference_NN [_NN 5_CD ]_NN ]_NN ._. Unlike_IN Pol_NNP ,_, TK_NNP is_VBZ not_RB
        essential_JJ for_IN virus_NN replication_NN in_IN cell_NN culture_NN [_NN 7_CD ]_NN ,_,
        although_IN 
        in_IN vivo_NN analyses_NNS implicate_VB it_PRP in_IN HSV_NNP
        virulence_NN ,_, pathogenicity_NN and_CC reactivation_NN from_IN latency_NN [_NN 4_CD
        8_CD 16_CD 22_CD ]_NN ._. Since_IN ACV_NNP and_CC PCV_NNP are_VBP dependent_JJ upon_IN HSV_NNP TK_NNP for_IN
        monophosphorylation_NN ,_, an_DT event_NN obligatory_JJ for_IN the_DT formation_NN
        of_IN the_DT active_JJ triphosphate_NN inhibitor_NN [_NN 14_CD ]_NN ,_, ACV_NNP risolates_NNS
        often_RB exhibit_NN high_JJ levels_NNS of_IN cross-resistance_JJ to_TO PCV_NNP [_NN 2_CD 3_CD
        ]_NN ._.
        Viral_NNP populations_NNS are_VBP naturally_RB heterogeneous_JJ ;_: there_EX are_VBP
        approximately_RB 6_CD to_TO 8_CD TK_NNP deficient_NN variants_NNS per_IN 10_CD
        4_CD plaque-forming_JJ units_NNS (_( PFU_NNP )_) of_IN HSV-_NNP 1_CD (_( laboratory_NN strains_NNS
        and_CC clinical_JJ isolates_VBZ )_) that_WDT have_VBP never_RB been_VBN exposed_VBN to_TO
        antiviral_JJ selection_NN [_NN 6_CD 13_CD 15_CD 17_CD ]_NN ._. Resistance_NNP to_TO
        nucleoside_NN inhibitors_NNS of_IN HSV_NNP arises_VBZ readily_RB in_IN tissue_NN
        culture_NN probably_RB by_IN selection_NN of_IN pre-existing_JJ mutants_NNS [_NN 10_CD
        13_CD 18_CD ]_NN ._. Moreover_RB ,_, Field_NNP 
        et_CC al_NN ._. [_NN 9_CD ]_NN demonstrated_VBD sequential_NN
        HSV_NNP inoculation_NN from_IN mouse_NN to_TO mouse_NN receiving_VBG sub-optimal_JJ
        ACV_NNP therapy_NN led_VBN to_TO the_DT selection_NN and_CC amplification_NN of_IN
        resistant_JJ virus_NN 
        in_IN vivo_NN ._. After_IN four_CD serial_NN passages_NNS
        in_IN the_DT immunocompetent_NN mice_NNS ,_, the_DT infection_NN became_VBD
        completely_RB refractory_JJ to_TO ACV_NNP treatment_NN ._.
        Acyclovir_NNP has_VBZ been_VBN in_IN part_NN superceded_VBD by_IN the_DT oral_JJ
        prodrugs_NNS valaciclovir_NN (_( VCV_NNP )_) and_CC famciclovir_NN (_( FCV_NNP )_) ,_, the_DT
        latter_JJ being_NN the_DT oral_JJ version_NN of_IN PCV_NNP [_NN 20_CD 24_CD ]_NN ._. No_DT
        comparative_JJ studies_NNS of_IN the_DT emergence_NN of_IN resistance_NN
        following_VBG sub-optimal_JJ VCV_NNP or_CC FCV_NNP have_VBP been_VBN reported_VBN and_CC
        therefore_RB set_VBN out_IN to_TO to_TO select_VB for_IN HSV-_NNP 1_CD and_CC HSV-_NNP 2_CD isolates_VBZ
        resistant_JJ to_TO ACV_NNP and_CC PCV_NNP after_IN using_VBG prodrug_NN selection_NN ._.
      
      
        Materials_NNS and_CC Methods_NNP
        
          Cell_NNP lines_NNS and_CC virus_NN strains_NNS
          MRC-_NNP 5_CD (_( pass_VB 18_CD -_: 25_CD )_) and_CC Vero_NNP were_VBD grown_VBN in_IN Dulbecco_NNP 's_POS
          modified_VBN Eagle_NNP 's_POS medium_NN (_( DMEM_NNP )_) supplemented_JJ with_IN 10_CD %_NN
          fetal_JJ calf_NN serum_NN (_( FCS_NNP )_) and_CC incubated_JJ at_IN 37_CD °_NN C_NNP ,_, 5_CD %_NN CO_NNP 
          2_CD ._. Vero_NNP cells_NNS were_VBD utilized_JJ for_IN virus_NN
          plaque_NN purification_NN and_CC protein_NN lysate_NN preparations_NNS and_CC
          MRC-_NNP 5_CD cells_NNS were_VBD used_VBN for_IN PRA_NNP and_CC PEA_NNP ._. TK-negative_NNP (_( TK_NNP -_: )_)
          human_JJ osteosarcoma_NN (_( 143_CD )_) cells_NNS were_VBD propagated_JJ in_IN the_DT
          medium_NN described_VBD above_IN and_CC utilized_JJ for_IN the_DT 3_CD H-_NNP thymidine_NN
          kinase_NN enzymatic_JJ assay_NN ._.
          Virus_NNP stocks_NNS were_VBD prepared_VBN by_IN inoculating_VBG cells_NNS at_IN
          0_CD ._. 01_CD plaque-forming_JJ units_NNS per_IN MRC-_NNP 5_CD cell_NN (_( PFU_NNP /_NN cell_NN )_) ._.
          Laboratory_NN virus_NN strains_NNS utilized_JJ were_VBD HSV-_NNP 1_CD SC_NNP 16_CD and_CC
          HSV-_NNP 2_CD SB_NNP 5_CD ._. SC_NNP 16_CD was_VBD kindly_RB provided_VBN by_IN Dr_NNP ._. Sharon_NNP Safrin_NNP
          (_( Gilead_NNP Sciences_NNPS ,_, CA_NNP )_) ._. SB_NNP 5_CD (_( ATCC_NNP ;_: VR-_NNP 2546_CD )_) was_VBD
          plaque-purified_JJ from_IN HSV-_NNP 2_CD 333_CD kindly_RB provided_VBN by_IN Dr_NNP ._.
          Priscilla_NNP Schaffer_NNP (_( University_NNP of_IN Pennsylvania_NNP ,_, PA_NNP )_) at_IN
          passage_NN 6_CD ._.
        
        
          Antiviral_NNP agents_NNS
          PCV_NNP and_CC FCV_NNP were_VBD synthesized_JJ at_IN GlaxoSmithKline_NNP ._. VCV_NNP
          was_VBD extracted_VBN from_IN Valtrex_NNP ™_NN tablets_NNS and_CC purity_NN was_VBD
          confirmed_VBN by_IN HPLC_NNP ._.
        
        
          Animal_NNP inoculation_NN and_CC treatment_NN
          Female_NNP BALB_NNP /_NN c_SYM mice_NNS (_( 18_CD -_: 20_CD g_SYM ;_: Charles_NNP River_NNP ,_, Raleigh_NNP ,_,
          NC_NNP )_) were_VBD infected_JJ intradermally_RB in_IN both_DT ear_NN pinnae_NN with_IN
          20_CD μl_NN of_IN virus_NN suspension_NN containing_VBG 10_CD 5_CD PFU_NNP of_IN HSV_NNP as_RB
          previously_RB described_VBD [_NN 1_CD ]_NN ._. The_DT same_JJ viral_JJ challenge_NN was_VBD
          used_VBN for_IN each_DT subsequent_JJ in_IN vivo_NN passage_NN ._. VCV_NNP or_CC FCV_NNP were_VBD
          administered_VBN via_IN drinking_NN water_NN at_IN either_DT 1_CD mg_NN /_NN ml_NN (_( a_DT dose_NN
          previously_RB shown_VBN to_TO be_VB a_DT highly_RB effective_JJ [_NN 23_CD ]_NN ;_: and_CC D_NNP
          Sutton_NNP ,_, unpublished_JJ observations_NNS )_) or_CC 0_CD ._. 2_CD mg_NN /_NN ml_NN
          (_( suboptimal_NN treatment_NN )_) from_IN the_DT time_NN of_IN infection_NN until_IN
          day_NN 4_CD post-infection_JJ ._. No_DT significant_JJ difference_NN in_IN daily_JJ
          consumption_NN between_IN either_DT of_IN the_DT treated_VBN groups_NNS or_CC the_DT
          placebo_NN group_NN (_( drug-free_JJ water_NN )_) was_VBD observed_VBN ._. Daily_JJ drug_NN
          intake_NN equated_VBN to_TO 75_CD mg_NN /_NN kg_NN or_CC 15_CD mg_NN /_NN kg_NN ,_, for_IN the_DT 1_CD mg_NN /_NN ml_NN
          and_CC 0_CD ._. 2_CD mg_NN /_NN ml_NN doses_NNS ,_, respectively_RB ._.
          To_TO facilitate_VB processing_NN of_IN blinded_JJ samples_NNS ,_, a_DT coding_VBG
          system_NN using_VBG sample_NN number-passage_JJ number_NN was_VBD applied_VBN ._.
          Virus_NNP sample_NN numbers_NNS 1_CD through_IN 15_CD were_VBD HSV-_NNP 1_CD ,_, and_CC 16_CD
          through_IN 30_CD were_VBD HSV-_NNP 2_CD ._. The_DT ears_NNS from_IN one_CD mouse_NN were_VBD
          pooled_VBN (_( passage_NN number_NN 1_CD inoculation_NN )_) and_CC used_VBN to_TO
          inoculate_NN the_DT ear_NN pinnae_NN of_IN one_CD mouse_NN (_( passage_NN number_NN 2_LS )_) ._.
          There_EX were_VBD five_CD replicate_VB mice_NNS per_IN treatment_NN group_NN
          (_( either_CC suboptimally_RB treated_VBN with_IN 0_CD ._. 2_CD mg_NN /_NN ml_NN FCV_NNP ,_, VCV_NNP or_CC
          placebo-treated_JJ )_) and_CC isolates_VBZ from_IN seven_CD serial_NN 
          in_IN vivo_NN passages_NNS examined_VBD ._. Five_CD
          individual_JJ plaques_NNS were_VBD purified_JJ three_CD times_NNS to_TO
          homogeneity_NN from_IN the_DT single_JJ drug-resistant_JJ virus_NN mixture_NN
          identified_VBN after_IN 
          in_IN vivo_NN passage_NN ,_, 14_CD -_: P_NN 4_CD (_( sample_NN 14_CD ,_,
          passage_NN 4_LS )_) ._. The_DT clonal_NN purified_JJ isolates_VBZ from_IN this_DT sample_NN
          were_VBD designated_VBN 14_CD -_: P_NN 4_CD A-E_NNP ._.
          The_DT 
          in_IN vivo_NN pathogenicity_NN of_IN selected_VBN
          virus_NN preparations_NNS was_VBD assessed_VBN in_IN mice_NNS by_IN monitoring_VBG
          lesion_NN severity_NN for_IN 14_CD days_NNS following_VBG inoculation_NN of_IN the_DT
          left_NN ear_NN pinna_NN with_IN 5_CD ×_NN 10_CD 5_CD PFU_NNP ._. Cumulative_NNP lesion_NN scores_NNS
          (_( day_NN 0_CD -_: 14_CD )_) were_VBD then_RB calculated_VBN from_IN the_DT individual_JJ daily_JJ
          scores_NNS ._.
        
        
          Virus_NNP isolation_NN and_CC in_IN vitro_NN assays_NNS
          Virus_NNP stocks_NNS were_VBD prepared_VBN as_IN described_VBN previously_RB [_NN
          17_CD ]_NN ,_, titrated_JJ and_CC characterized_VBN by_IN PRA_NNP and_CC PEA_NNP ._. On_IN day_NN
          4_CD post-infection_JJ ,_, mice_NNS were_VBD euthanized_JJ ,_, and_CC both_DT ear_NN
          pinnae_NN removed_VBN and_CC pooled_VBN in_IN coded_VBN tubes_NNS ,_, one_CD tube_NN per_IN
          mouse_NN ._. The_DT code_NN was_VBD not_RB broken_VBN until_IN all_DT tissue_NN culture_NN
          assays_NNS had_VBD been_VBN completed_VBN ._. The_DT tissue_NN was_VBD homogenized_JJ and_CC
          virus_NN stocks_NNS were_VBD prepared_VBN in_IN MRC-_NNP 5_CD cells_NNS from_IN cell-free_JJ
          supernatants_NNS ._. Following_VBG virus_NN adsorption_NN onto_IN the_DT MRC-_NNP 5_CD
          monolayer_NN ,_, two_CD washes_NNS with_IN phosphate-buffered_JJ saline_NN were_VBD
          performed_VBN to_TO remove_VB any_DT residual_JJ antiviral_JJ drug_NN ._.
          Cell-free_NNP virus_NN was_VBD harvested_VBN ,_, titrated_JJ and_CC characterized_VBN
          by_IN PRA_NNP and_CC PEA_NNP prior_RB to_TO use_VB in_IN subsequent_JJ passage_NN
          experiments_NNS (_( Figure_NN 1_LS )_) ._. All_DT PRA_NNP ,_, PEA_NNP and_CC in_IN vivo_NN studies_NNS
          were_VBD carried_VBN out_IN using_VBG virus_NN that_WDT had_VBD undergone_VBN a_DT single_NN
          in_IN vitro_NN passage_NN ._. PRAs_NNP were_VBD performed_VBN in_IN MRC-_NNP 5_CD cells_NNS as_IN
          described_VBN previously_RB [_NN 17_CD ]_NN ._. The_DT plating_VBG efficiency_NN of_IN
          the_DT virus_NN preparations_NNS generated_VBN 
          in_IN vivo_NN was_VBD determined_VBN according_VBG to_TO
          the_DT method_NN developed_VBN by_IN Hall_NNP 
          et_CC al_NN ._. with_IN minor_JJ modifications_NNS [_NN
          13_CD ]_NN as_IN reported_VBN previously_RB [_NN 17_CD ]_NN ._. Briefly_NNP ,_, six_CD serial_NN
          10_CD -_: fold_VB dilutions_NNS of_IN virus_NN were_VBD inoculated_JJ onto_IN MRC-_NNP 5_CD
          cells_NNS in_IN the_DT absence_NN of_IN antiviral_JJ drug_NN or_CC in_IN the_DT presence_NN
          of_IN either_DT ACV_NNP or_CC PCV_NNP at_IN a_DT concentration_NN of_IN antiviral_JJ 10_CD
          times_NNS higher_JJR than_IN the_DT average_JJ IC_NNP 
          50_CD for_IN wild_JJ type_NN parental_JJ HSV-_NNP 1_CD and_CC
          HSV-_NNP 2_CD ,_, respectively_RB ._. The_DT mutation_NN frequency_NN was_VBD
          calculated_VBN as_IN follows_VBZ :_: mutation_NN frequency_NN =_SYM (_( virus_NN titer_NN
          in_IN the_DT presence_NN of_IN drug_NN )_) /_NN (_( virus_NN titer_NN in_IN the_DT absence_NN of_IN
          drug_NN )_) ._. The_DT frequency_NN is_VBZ often_RB expressed_VBN as_IN a_DT plating_VBG
          efficiency_NN ,_, or_CC percentage_NN of_IN viruses_NNS that_WDT are_VBP resistant_NN ,_,
          which_WDT is_VBZ calculated_VBN as_IN percent_NN resistant_JJ =_SYM (_( mutation_NN
          frequency_NN )_) ×_NN 100_CD ._.
        
        
          Antibodies_NNP and_CC biochemical_JJ assays_NNS
          Western_JJ blot_NN analysis_NN was_VBD performed_VBN as_IN described_VBN
          previously_RB [_NN 18_CD ]_NN ._. Viral_NNP TK_NNP activity_NN was_VBD determined_VBN by_IN a_DT
          modification_NN of_IN the_DT method_NN utilized_JJ by_IN Coen_NNP and_CC Schaffer_NNP
          [_NN 4_CD ]_NN as_IN described_VBN in_IN [_NN 17_CD ]_NN ._. Primers_NNP utilized_JJ for_IN TK_NNP
          sequencing_VBG were_VBD described_VBN previously_RB [_NN 18_CD ]_NN ._.
        
      
      
        Results_NNS
        
          Virus_NNP yield_VB after_IN antiviral_JJ treatment_NN
          To_TO evaluate_VB efficacy_NN of_IN prodrug_NN treatment_NN in_IN this_DT
          model_NN ,_, VCV_NNP and_CC FCV_NNP were_VBD provided_VBN in_IN the_DT drinking_NN water_NN at_IN
          1_CD ._. 0_CD mg_NN /_NN ml_NN or_CC at_IN 0_CD ._. 2_CD mg_NN /_NN ml_NN (_( sub-optimal_JJ treatment_NN )_) for_IN
          mice_NNS infected_VBN with_IN either_DT HSV-_NNP 1_CD SC_NNP 16_CD or_CC HSV-_NNP 2_CD SB_NNP 5_CD ._. Titers_NNP
          (_( day_NN 4_CD post-infection_JJ )_) of_IN approximately_RB 4_CD ._. 5_CD log_VB 
          10_CD virus_NN per_IN ear_NN were_VBD recovered_VBN from_IN
          placebo-treated_JJ mice_NNS ,_, regardless_RB of_IN virus_NN type_NN (_( Table_NNP 1_LS )_) ._.
          As_IN expected_VBN ,_, a_DT significant_JJ reduction_NN in_IN virus_NN yield_NN
          (_( greater_JJR than_IN 3_CD ._. 5_CD log_VB 
          10_CD decrease_VB )_) was_VBD noted_VBN for_IN mice_NNS
          treated_VBN with_IN either_DT VCV_NNP or_CC FCV_NNP at_IN 1_CD ._. 0_CD mg_NN /_NN ml_NN following_VBG
          infection_NN with_IN either_DT HSV-_NNP 1_CD or_CC HSV-_NNP 2_CD ._.
          In_IN the_DT same_JJ experiment_NN ,_, virus_NN yield_NN from_IN
          suboptimally-treated_JJ mice_NNS was_VBD reduced_VBN approximately_RB
          1_CD ._. 6_CD -_: 2_CD ._. 6_CD log_VB 
          10_CD compared_VBN to_TO placebo-treated_JJ mice_NNS ,_,
          and_CC these_DT data_NNS are_VBP consistent_JJ with_IN a_DT previous_JJ report_NN in_IN
          which_WDT ACV_NNP was_VBD administered_VBN at_IN a_DT concentration_NN of_IN 0_CD ._. 25_CD
          mg_NN /_NN ml_NN [_NN 10_CD ]_NN ._. At_IN 0_CD ._. 2_CD mg_NN /_NN ml_NN ,_, viral_JJ replication_NN ,_, albeit_IN
          reduced_VBN ,_, was_VBD still_RB ongoing_JJ ,_, a_DT prerequisite_NN for_IN the_DT 
          in_IN vivo_NN selection_NN of_IN resistant_JJ
          HSV_NNP ._.
          A_DT reproducible_JJ difference_NN in_IN virus_NN yield_NN between_IN the_DT
          two_CD antiviral_JJ treatment_NN groups_NNS at_IN the_DT suboptimal_NN
          concentration_NN was_VBD evident_JJ ,_, regardless_RB of_IN virus_NN type_NN ._. For_IN
          HSV-_NNP 1_CD ,_, the_DT difference_NN in_IN titer_NN between_IN VCV-treated_NNP mice_NNS
          (_( 2_CD ._. 45_CD log_VB 
          10_CD PFU_NNP /_NN ml_NN )_) and_CC FCV-treated_NNP (_( 2_CD ._. 92_CD log_VB 
          10_CD PFU_NNP /_NN ml_NN )_) was_VBD statistically_RB
          significant_JJ (_( p_NN =_SYM 0_CD ._. 049_CD )_) ._. Similarly_RB for_IN HSV-_NNP 2_CD ,_, VCV_NNP at_IN 0_CD ._. 2_CD
          mg_NN /_NN ml_NN was_VBD significantly_RB more_RBR effective_JJ than_IN FCV_NNP in_IN this_DT
          mouse_NN model_NN ._. Titers_NNP from_IN VCV-_NNP or_CC FCV-treated_NNP mice_NNS were_VBD
          2_CD ._. 06_CD log_VB 
          10_CD PFU_NNP /_NN ml_NN or_CC 2_CD ._. 55_CD log_VB 
          10_CD PFU_NNP /_NN ml_NN ,_, respectively_RB (_( p_NN =_SYM 0_CD ._. 001_CD )_) ._.
          Similar_JJ trends_NNS were_VBD noted_VBN when_WRB the_DT antivirals_NNS were_VBD
          compared_VBN at_IN 1_CD ._. 0_CD mg_NN /_NN ml_NN for_IN both_DT HSV-_NNP 1_CD and_CC HSV-_NNP 2_CD (_( Table_NNP 1_LS )_) ._.
          These_DT observations_NNS can_MD not_RB be_VB accounted_VBN for_IN by_IN
          differences_NNS in_IN exposure_NN to_TO ACV_NNP and_CC PCV_NNP since_IN oral_JJ
          administration_NN of_IN VCV_NNP and_CC FCV_NNP results_NNS in_IN almost_RB identical_JJ
          blood_NN concentration-time_JJ curves_NNS for_IN ACV_NNP and_CC PCV_NNP [_NN 11_CD ]_NN ._.
          A_DT more_RBR probable_JJ explanation_NN is_VBZ that_IN ACV_NNP is_VBZ approximately_RB
          four-fold_RB more_RBR potent_JJ than_IN PCV_NNP in_IN murine_NN cells_NNS [_NN 21_CD ]_NN
          ._.
          To_TO select_VB and_CC amplify_VB drug-resistant_JJ HSV_NNP in_IN mice_NNS ,_, a_DT
          total_NN of_IN seven_CD consecutive_JJ passages_NNS were_VBD performed_VBN ,_, and_CC
          progeny_NN virus_NN from_IN each_DT passage_NN was_VBD characterized_VBN 
          in_IN vitro_NN by_IN PRA_NNP and_CC PEA_NNP ._.
        
        
          PRA_NNP susceptibility_NN
          
            Drug-selected_NNP HSV-_NNP 1_CD SC_NNP 16_CD
            Mean_VB PCV_NNP susceptiblities_NNS of_IN the_DT HSV-_NNP 1_CD isolates_VBZ (_( n_NN =_SYM
            105_CD )_) from_IN passages_NNS 1_CD through_IN 7_CD are_VBP listed_VBN in_IN Table_NNP 2_CD ._.
            All_DT isolates_VBZ from_IN mice_NNS treated_VBN with_IN either_DT placebo_NN or_CC
            FCV_NNP remained_VBD sensitive_JJ to_TO PCV_NNP (_( IC_NNP 
            50_CD s_VBZ ranging_VBG from_IN 0_CD ._. 28_CD -_: 1_CD ._. 50_CD μg_NN /_NN ml_NN )_)
            and_CC to_TO ACV_NNP (_( results_NNS not_RB shown_VBN )_) according_VBG to_TO the_DT
            standard_JJ resistance_NN breakpoint_NN criteria_NNS ,_, whereas_IN
            isolates_VBZ from_IN mice_NNS treated_VBN with_IN VCV_NNP had_VBD PCV_NNP IC_NNP 
            50_CD s_VBZ ranging_VBG from_IN 0_CD ._. 31_CD -_: 8_CD ._. 3_LS μg_NN /_NN ml_NN ._.
            One_CD isolate_VB (_( 4_CD th_NN passage_NN ;_: 14_CD -_: P_NN 4_LS )_) in_IN this_DT treatment_NN
            group_NN was_VBD confirmed_VBN as_IN resistant_JJ to_TO both_DT PCV_NNP (_( IC_NNP 
            50_CD =_SYM 8_CD ._. 3_CD μg_NN /_NN ml_NN )_) and_CC ACV_NNP (_( IC_NNP 
            50_CD =_SYM 9_CD ._. 5_CD μg_NN /_NN ml_NN )_) ._. Generally_RB ,_, test_NN
            sample_NN IC_NNP 
            50_CD s_VBZ varied_VBN within_IN two-fold_JJ of_IN the_DT
            non-passaged_JJ control_NN virus_NN IC_NNP 
            50_CD ,_, within_IN each_DT particular_JJ assay_NN
            (_( data_NNS not_RB shown_VBN )_) ;_: however_RB ,_, isolate_VB 14_CD -_: P_NN 4_CD was_VBD clearly_RB
            different_JJ ,_, with_IN an_DT IC_NNP 
            50_CD greater_JJR than_IN 11_CD -_: fold_VB over_IN the_DT
            control_NN virus_NN IC_NNP 
            50_CD for_IN both_DT PCV_NNP and_CC ACV_NNP ._.
            Interestingly_RB ,_, although_IN 14_CD -_: P_NN 4_CD was_VBD resistant_JJ ,_, the_DT
            third_JJ pass_NN isolate_VB for_IN this_DT sample_NN was_VBD completely_RB
            sensitive_JJ to_TO both_DT antiviral_JJ agents_NNS (_( ACV_NNP IC_NNP 
            50_CD =_SYM 0_CD ._. 16_CD μg_NN /_NN ml_NN ;_: PCV_NNP IC_NNP 
            50_CD =_SYM 0_CD ._. 53_CD μg_NN /_NN ml_NN )_) ._. Therefore_RB ,_, the_DT PRA_NNP
            provided_VBD no_DT early_JJ indication_NN at_IN pass_NN 3_CD of_IN potentially_RB
            increasing_VBG resistant_JJ variants_NNS upon_IN subsequent_JJ passage_NN ._.
            Furthermore_RB ,_, the_DT resulting_VBG virus_NN preparation_NN from_IN
            subsequent_JJ passaging_VBG of_IN 14_CD -_: P_NN 4_CD reverted_VBN to_TO a_DT sensitive_JJ
            phenotype_NN (_( ACV_NNP IC_NNP 
            50_CD =_SYM 0_CD ._. 74_CD μg_NN /_NN ml_NN ;_: PCV_NNP IC_NNP 
            50_CD =_SYM 0_CD ._. 74_CD μg_NN /_NN ml_NN )_) ,_, although_IN
            suboptimal_NN treatment_NN was_VBD still_RB utilized_JJ ._.
          
          
            Drug-selected_NNP HSV-_NNP 2_CD SB_NNP 5_CD
            Mean_VB PCV_NNP susceptiblities_NNS of_IN the_DT HSV-_NNP 2_CD isolates_VBZ (_( n_NN =_SYM
            105_CD )_) from_IN passages_NNS 1_CD through_IN 7_CD are_VBP listed_VBN in_IN Table_NNP 3_CD ._.
            No_DT resistant_JJ HSV-_NNP 2_CD emerged_VBD among_IN the_DT total_NN of_IN 105_CD HSV-_NNP 2_CD
            isolates_VBZ tested_VBN from_IN the_DT three_CD treatment_NN groups_NNS (_( PCV_NNP IC_NNP
            
            50_CD s_VBZ ranged_VBN from_IN 0_CD ._. 66_CD -_: 1_CD ._. 85_CD μg_NN /_NN ml_NN
            across_IN treatment_NN groups_NNS )_) ._. These_DT results_NNS were_VBD confirmed_VBN
            when_WRB the_DT same_JJ isolates_VBZ were_VBD tested_VBN for_IN susceptibility_NN
            to_TO ACV_NNP (_( results_NNS not_RB shown_VBN )_) and_CC all_PDT the_DT IC_NNP 
            50_CD s_VBZ were_VBD sensitive_JJ over_IN a_DT similar_JJ
            range_NN as_IN PCV_NNP ._. As_IN with_IN HSV-_NNP 1_CD ,_, the_DT HSV-_NNP 2_CD test_NN samples_NNS
            were_VBD generally_RB within_IN two-fold_JJ of_IN the_DT control_NN virus_NN IC_NNP 
            50_CD (_( data_NNS not_RB shown_VBN )_) ._.
          
        
        
          PEA_NNP profiling_VBG
          
            Drug-selected_NNP HSV-_NNP 1_CD SC_NNP 16_CD
            The_DT HSV-_NNP 1_CD control_NN virus_NN preparation_NN contained_VBD
            between_IN 0_CD ._. 002_CD -_: 0_CD ._. 02_CD %_NN ACV_NNP rvirus_JJ and_CC 0_CD ._. 004_CD -_: 0_CD ._. 009_CD %_NN PCV_NNP r_LS ,_,
            which_WDT equates_VBZ to_TO an_DT average_NN of_IN 6_CD ._. 6_CD ACV_NNP rand_NNS 6_CD ._. 0_CD PCV_NNP
            rresistant_NN viruses_NNS per_IN 10_CD 5_CD PFU_NNP ._. Generally_RB ,_, the_DT
            proportion_NN of_IN PCV_NNP rvirus_JJ varied_VBD only_RB two-fold_JJ between_IN
            tests_NNS when_WRB compared_VBN to_TO the_DT control_NN virus_NN ,_, ranging_VBG from_IN
            0_CD ._. 004_CD to_TO 0_CD ._. 009_CD %_NN (_( data_NNS not_RB shown_VBN )_) ;_: however_RB ,_, three_CD serial_NN
            samples_NNS in_IN the_DT VCV-treatment_NNP group_NN ,_, 14_CD -_: P_NN 2_CD ,_, 14_CD -_: P_NN 3_CD and_CC
            14_CD -_: P_NN 4_CD ,_, clearly_RB showed_VBD a_DT substantial_JJ increase_NN in_IN the_DT
            proportion_NN of_IN resistant_JJ virus_NN relative_JJ to_TO the_DT wild_JJ type_NN
            control_NN ,_, specifically_RB an_DT 11_CD -_: ,_, 300_CD -_: and_CC 8800_CD -_: fold_VB
            increase_NN ,_, respectively_RB (_( 14_CD -_: P_NN 2_CD ,_, 0_CD ._. 002_CD %_NN ;_: 14_CD -_: P_NN 3_CD ,_, 2_CD %_NN ;_: and_CC
            14_CD -_: P_NN 4_CD ,_, 44_CD %_NN PCV_NNP r_LS )_) ._. Although_IN passage_NN 3_CD preparation_NN
            contains_VBZ a_DT two_CD log_NN increase_NN in_IN resistant_JJ virus_NN compared_VBN
            to_TO passage_NN 2_CD ,_, this_DT level_NN is_VBZ insufficient_JJ to_TO
            significantly_RB increase_VB the_DT IC_NNP 
            50_CD ._. Consistent_NNP with_IN the_DT failure_NN to_TO
            establish_VB an_DT infection_NN refractory_JJ to_TO treatment_NN ,_, the_DT
            proportion_NN of_IN resistant_JJ virus_NN decreased_VBD to_TO 0_CD ._. 08_CD %_NN PCV_NNP
            rand_NNS 0_CD ._. 05_CD %_NN ACV_NNP rby_NN passage_NN 5_CD ._.
          
          
            Drug-selected_NNP HSV-_NNP 2_CD SB_NNP 5_CD
            The_DT HSV-_NNP 2_CD control_NN virus_NN preparation_NN contained_VBD
            between_IN 0_CD ._. 24_CD -_: 0_CD ._. 40_CD %_NN ACV_NNP rand_NNS 0_CD ._. 13_CD -_: 0_CD ._. 40_CD %_NN PCV_NNP rvirus_JJ ,_,
            which_WDT equates_VBZ to_TO an_DT average_NN of_IN 3_CD ._. 1_CD ACV_NNP rand_NNS PCV_NNP
            rviruses_NNS per_IN 10_CD 3_CD PFU_NNP ._. Generally_RB ,_, the_DT proportion_NN of_IN
            resistant_JJ virus_NN varied_VBD only_RB three-fold_JJ between_IN tests_NNS
            when_WRB compared_VBN to_TO the_DT control_NN virus_NN (_( data_NNS not_RB shown_VBN )_) ,_,
            however_RB a_DT continual_JJ increase_NN in_IN the_DT proportion_NN of_IN
            resistant_JJ virus_NN was_VBD seen_VBN with_IN the_DT sample_NN 30_CD passages_NNS
            (_( VCV_NNP treatment_NN group_NN )_) ._. The_DT proportion_NN of_IN PCV_NNP rvirus_JJ in_IN
            sample_NN 30_CD increased_VBN from_IN 0_CD ._. 40_CD %_NN to_TO 2_CD ._. 8_CD %_NN to_TO 12_CD ._. 2_LS %_NN
            throughout_IN serial_NN passages_NNS 1_CD through_IN 3_CD and_CC declined_VBD to_TO
            0_CD ._. 2_CD %_NN by_IN passage_NN 4_CD ._. All_DT of_IN these_DT isolates_VBZ were_VBD
            susceptible_JJ to_TO PCV_NNP by_IN the_DT PRA_NNP (_( IC_NNP 
            50_CD s_VBZ for_IN sample_NN 30_CD ,_, passage_NN 2_CD
            through_IN 4_CD ,_, were_VBD 0_CD ._. 79_CD ,_, 0_CD ._. 90_CD and_CC 1_CD ._. 2_CD μg_NN /_NN ml_NN ,_,
            respectively_RB )_) ._.
          
        
        
          Analysis_NNP of_IN drug-resistant_JJ isolate_VB
          Of_IN 210_CD HSV_NNP isolates_VBZ from_IN mice_NNS treated_VBD sub-optimally_JJ
          with_IN FCV_NNP or_CC VCV_NNP ,_, or_CC with_IN placebo_NN ,_, only_RB one_CD HSV-_NNP 1_CD isolate_VB ,_,
          14_CD -_: P_NN 4_CD was_VBD identified_VBN in_IN the_DT PRA_NNP as_IN an_DT antiviral-resistant_JJ
          isolate_VB ._. Five_CD single_JJ plaques_NNS from_IN 14_CD -_: P_NN 4_CD were_VBD isolated_VBN
          after_IN three_CD rounds_NNS of_IN plaque_NN purification_NN and_CC
          characterized_VBN ._. The_DT clonal_NN isolates_VBZ were_VBD tested_VBN for_IN
          susceptibility_NN to_TO using_VBG the_DT PRA_NNP and_CC were_VBD found_VBN to_TO be_VB
          highly_RB resistant_JJ to_TO ACV_NNP (_( ACV_NNP IC_NNP 
          50_CD s_VBZ >_NN 25_CD μg_NN /_NN ml_NN )_) and_CC PCV_NNP (_( Table_NNP 4_CD ;_:
          PCV_NNP IC_NNP 
          50_CD s_VBZ >_NN 25_CD μg_NN /_NN ml_NN )_) ,_, although_IN
          susceptible_JJ to_TO foscarnet_NN ._.
          Western_JJ blot_NN analysis_NN showed_VBD that_IN each_DT clonal_NN isolate_VB
          produced_VBN a_DT truncated_JJ TK_NNP polypeptide_NN compared_VBN to_TO the_DT wild_JJ
          type_NN TK_NNP protein_NN product_NN of_IN approximately_RB 43_CD kD_NN (_( Figure_NN
          2_LS )_) ._. Moreover_RB ,_, all_DT five_CD clones_NNS were_VBD defective_JJ for_IN TK_NNP
          activity_NN compared_VBN with_IN HSV-_NNP 1_CD SC_NNP 16_CD in_IN a_DT 3_CD H-_NNP thymidine_NN
          kinase_NN assay_NN (_( Table_NNP 4_LS )_) ._. Sequence_NNP analysis_NN of_IN the_DT TK_NNP
          coding_VBG region_NN from_IN all_DT five_CD plaque_NN isolates_VBZ identified_VBN a_DT
          G_NNP nucleotide_NN insertion_NN in_IN the_DT homopolymeric_JJ hot-spot_JJ G_NNP 7_CD
          tract_NN at_IN nucleotide_NN 435_CD ,_, a_DT common_JJ mutation_NN present_JJ in_IN
          other_JJ ACV_NNP rHSV_NN isolates_VBZ [_NN 18_CD 19_CD ]_NN ._. This_DT base_NN insertion_NN
          produced_VBD a_DT frame_NN shift_NN in_IN the_DT coding_VBG sequence_NN ,_, resulting_VBG
          in_IN a_DT loss_NN of_IN the_DT ATP_NNP /_NN nucleoside-binding_JJ site_NN and_CC the_DT
          creation_NN of_IN a_DT premature_JJ stop_NN codon_NN at_IN amino_JJ acid_NN 228_CD to_TO
          encode_NN a_DT truncated_JJ 28_CD kD_NN TK_NNP polypeptide_NN ._.
          Lastly_NNP ,_, the_DT 
          in_IN vivo_NN pathogenicities_NNS of_IN 14_CD -_: P_NN 4_CD
          and_CC one_CD of_IN its_PRP$ clonal_NN isolates_VBZ (_( 14_CD -_: P_NN 4_CD E_NNP )_) were_VBD compared_VBN
          with_IN the_DT control_NN virus_NN ,_, HSV-_NNP 1_CD SC_NNP 16_CD ._. Isolate_NNP 14_CD -_: P_NN 4_CD
          containing_VBG 45_CD %_NN resistant_JJ virus_NN caused_VBD significant_JJ
          clinical_JJ disease_NN in_IN mice_NNS ,_, only_RB marginally_RB less_RBR severe_JJ
          than_IN that_DT observed_VBD with_IN HSV-_NNP 1_CD SC_NNP 16_CD ._. In_IN marked_JJ contrast_NN ,_,
          mice_NNS inoculated_JJ with_IN the_DT plaque-purified_JJ isolate_VB ,_, 14_CD -_: P_NN 4_CD E_NNP ,_,
          developed_VBD a_DT mild_JJ infection_NN ._. The_DT cumulative_JJ disease_NN scores_NNS
          for_IN parental_JJ virus_NN control_NN HSV-_NNP 1_CD SC_NNP 16_CD ,_, 14_CD -_: P_NN 4_CD and_CC 14_CD -_: P_NN 4_CD E_NNP
          were_VBD 136_CD ,_, 96_CD and_CC 15_CD ,_, respectively_RB ._.
        
      
      
        Discussion_NNP
        HSV-_NNP 1_CD or_CC HSV-_NNP 2_CD isolates_VBZ were_VBD passaged_JJ serially_RB seven_CD
        times_NNS in_IN mice_NNS inoculated_JJ in_IN the_DT ear_NN pinnae_NN and_CC treated_VBN with_IN
        suboptimal_NN (_( 15_CD mg_NN /_NN kg_NN per_IN day_NN )_) concentrations_NNS of_IN FCV_NNP or_CC VCV_NNP
        to_TO select_VB resistant_JJ virus_NN ._. Despite_IN ongoing_JJ ,_, albeit_IN reduced_VBN ,_,
        viral_JJ replication_NN in_IN the_DT animals_NNS ,_, selection_NN of_IN resistant_JJ
        HSV_NNP with_IN the_DT prodrugs_NNS proved_VBD difficult_JJ ._. Interestingly_RB ,_, the_DT
        single_JJ drug-resistant_JJ isolate_VB identified_VBN from_IN this_DT study_NN
        reverted_VBN to_TO a_DT sensitive_JJ phenotype_NN upon_IN reinfection_NN ,_, even_RB
        with_IN suboptimal_NN antiviral_JJ treatment_NN ._.
        Although_IN virus_NN recovered_VBD at_IN passage_NN 4_CD from_IN one_CD of_IN five_CD
        mice_NNS treated_VBN with_IN VCV_NNP (_( 14_CD -_: P_NN 4_LS )_) was_VBD clearly_RB resistant_JJ in_IN the_DT
        PRA_NNP (_( IC_NNP 
        50_CD s_VBZ 8_CD ._. 3_CD and_CC 9_CD ._. 5_CD for_IN PCV_NNP and_CC ACV_NNP ,_,
        respectively_RB )_) ,_, the_DT preceding_VBG and_CC the_DT subsequent_JJ isolates_VBZ
        were_VBD sensitive_JJ according_VBG to_TO the_DT criteria_NNS for_IN defining_VBG
        resistance_NN ._. The_DT PEA_NNP identified_VBD a_DT gradual_JJ increase_NN in_IN the_DT
        proportion_NN of_IN resistant_JJ virus_NN from_IN 14_CD -_: P_NN 2_CD (_( 0_CD ._. 002_CD %_NN )_) to_TO 14_CD -_: P_NN 3_CD
        (_( ~_NN 2_CD %_NN )_) to_TO 14_CD -_: P_NN 4_CD (_( 44_CD %_NN )_) ._. However_RB ,_, for_IN the_DT most_JJS part_NN ,_, the_DT PEA_NNP
        data_NN did_VBD not_RB correlate_VBP with_IN the_DT eventual_JJ appearance_NN of_IN
        drug-resistant_JJ virus_NN as_IN defined_VBN by_IN the_DT PRA_NNP ._. Consistent_NNP with_IN
        this_DT ,_, an_DT earlier_JJR studied_VBN showed_VBD that_IN the_DT proportion_NN of_IN
        drug-resistant_JJ virus_NN in_IN a_DT preparation_NN needs_VBZ to_TO be_VB
        approximately_RB 50_CD %_NN before_IN resulting_VBG in_IN a_DT signficant_NN change_NN
        in_IN IC_NNP 
        50_CD [_NN 9_CD ]_NN ._.
        Biochemical_NNP characterization_NN of_IN the_DT 14_CD -_: P_NN 4_CD isolate_VB
        confirmed_VBN that_WDT impaired_VBN TK_NNP activity_NN was_VBD most_RBS likely_JJ
        responsible_JJ for_IN the_DT resistance_NN phenotype_NN ._. Sequence_NNP analysis_NN
        of_IN one_CD of_IN these_DT clonal_NN isolates_VBZ (_( 14_CD -_: P_NN 4_CD E_NNP )_) revealed_VBD insertion_NN
        of_IN an_DT extra_JJ G_NNP within_IN the_DT G_NNP 
        7_CD homopolymeric_JJ region_NN of_IN the_DT TK_NNP coding_VBG
        region_NN ._. This_DT mutation_NN has_VBZ also_RB been_VBN detected_VBN in_IN clinical_JJ
        isolates_VBZ from_IN patients_NNS immunocompromised_JJ [_NN 12_CD ]_NN or_CC with_IN
        AIDS_NNP [_NN 19_CD ]_NN as_RB well_RB as_IN resistant_JJ HSV_NNP selected_VBD in_IN tissue_NN
        culture_NN [_NN 15_CD 18_CD ]_NN ._. Interestingly_RB ,_, this_DT mutation_NN was_VBD
        present_JJ in_IN ACV_NNP rclinical_JJ isolates_VBZ obtained_VBN during_IN
        reactivation_NN in_IN the_DT absence_NN of_IN drug_NN pressure_NN ,_, as_RB well_RB as_IN in_IN
        ACV_NNP rstrains_NNS which_WDT evolved_VBD during_IN ACV_NNP therapy_NN and_CC were_VBD
        followed_VBN by_IN ACV-susceptible_NNP isolates_VBZ at_IN the_DT next_JJ
        reactivation_NN [_NN 19_CD ]_NN ._.
        It_PRP was_VBD surprising_JJ to_TO find_VB that_IN the_DT ACV-resistant_NNP virus_NN
        selected_VBN 
        in_IN vivo_NN was_VBD not_RB retained_VBN or_CC amplified_VBN
        in_IN subsequent_JJ passages_NNS despite_IN continued_JJ suboptimal_NN
        treatment_NN with_IN VCV_NNP ._. This_DT result_NN appears_VBZ to_TO be_VB in_IN direct_JJ
        contrast_NN to_TO that_DT of_IN Field_NNP [_NN 9_CD ]_NN who_WP found_VBD that_IN following_VBG
        selection_NN of_IN ACV-resistant_NNP virus_NN 
        in_IN vivo_NN ,_, such_JJ viruses_NNS remained_VBD
        refractory_JJ to_TO treatment_NN upon_IN subsequent_JJ passage_NN using_VBG
        suboptimal_NN treatment_NN with_IN ACV_NNP ._. The_DT reason_NN for_IN this_DT
        difference_NN is_VBZ unclear_JJ ._. However_RB ,_, the_DT failure_NN to_TO maintain_VB the_DT
        resistant_JJ virus_NN on_IN subsequent_JJ passage_NN suggests_VBZ that_IN the_DT
        pathogenicity_NN of_IN 14_CD -_: P_NN 4_CD may_MD have_VB been_VBN only_RB partially_RB
        attenuated_JJ relative_NN to_TO the_DT sensitive_JJ virus_NN and_CC indeed_RB the_DT
        pathogenicity_NN of_IN the_DT clonal_NN virus_NN isolate_VB ,_, 14_CD -_: P_NN 4_CD E_NNP ,_, was_VBD
        severely_RB attenuated_JJ ._. Further_RB studies_VBZ on_IN the_DT 14_CD -_: P_NN 4_CD clonal_NN
        isolates_VBZ and_CC the_DT clinical_JJ significance_NN of_IN their_PRP$
        attentuation_NN should_MD be_VB explored_JJ ._.
      
      
        Conclusions_NNP
        Sub-optimal_NNP therapy_NN of_IN immunocompetent_NN mice_NNS with_IN either_DT
        VCV_NNP or_CC FCV_NNP did_VBD not_RB readily_RB select_VB for_IN HSV-mutants_NNP resistant_JJ
        to_TO either_CC ACV_NNP or_CC PCV_NNP ,_, suggesting_VBG that_DT selection_NN of_IN
        resistance_NN with_IN either_DT prodrug_NN remains_VBZ difficult_JJ using_VBG this_DT
        system_NN ._. All_DT the_DT virus_NN isolates_VBZ from_IN each_DT serial_NN passage_NN
        were_VBD examined_VBN by_IN both_DT PRA_NNP and_CC PEA_NNP ._. The_DT former_NN is_VBZ widely_RB
        accepted_VBN as_IN the_DT gold_NN standard_JJ for_IN susceptibility_NN testing_NN of_IN
        HSV_NNP ,_, and_CC for_IN ACV_NNP ,_, a_DT correlation_NN between_IN PRA_NNP 
        in_IN vitro_NN IC_NNP 
        50_CD and_CC clinical_JJ outcome_NN has_VBZ been_VBN
        established_VBN ._. In_IN spite_NN of_IN this_DT ,_, the_DT PEA_NNP appears_VBZ to_TO have_VB
        potential_JJ as_IN an_DT adjunct_NN to_TO the_DT PRA_NNP by_IN providing_VBG earlier_JJR
        detection_NN of_IN the_DT emergence_NN of_IN resistant_JJ HSV_NNP ._. However_RB ,_, it_PRP is_VBZ
        important_JJ to_TO note_VB that_IN although_IN an_DT increase_NN in_IN the_DT number_NN
        resistant_JJ variants_NNS within_IN isolates_VBZ was_VBD readily_RB detected_VBN by_IN
        the_DT PEA_NNP ,_, clinically-resistant_JJ virus_NN did_VBD not_RB develop_VB in_IN the_DT
        immunocompetent_NN mice_NNS ._. Therefore_RB ,_, the_DT presence_NN of_IN resistant_JJ
        virus_NN within_IN an_DT isolate_VB ,_, even_RB at_IN levels_NNS substantially_RB above_IN
        background_NN ,_, does_VBZ not_RB in_IN itself_PRP indicate_VBP that_WDT increased_VBD
        resistance_NN will_MD follow_VB ,_, nor_CC does_VBZ it_PRP necessarily_RB predict_VBP
        clinical_JJ resistance_NN ._. It_PRP would_MD be_VB of_IN interest_NN to_TO apply_VB the_DT
        PEA_NNP to_TO an_DT extensive_JJ series_NN of_IN clinical_JJ isolates_VBZ ,_,
        particularly_RB isolates_VBZ obtained_VBN from_IN severely_RB
        immunocompromised_JJ patients_NNS ,_, in_IN order_NN to_TO evaluate_VB the_DT
        proportions_NNS of_IN resistant_JJ virus_NN that_WDT occur_VBP within_IN different_JJ
        clinical_JJ isolates_VBZ ._.
      
      
        Competing_VBG Interests_NNP
        None_NN declared_VBD ._.
      
    
  
